MiNK Therapeutics, Inc. Interest Expense
MiNK Therapeutics, Inc. (INKT) reported Interest Expense of -$2.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement
us-gaap:InterestExpense · last filed 2026-08-13
- MiNK Therapeutics, Inc. interest expense for the quarter ending 2026-06-30 was -$2.00K.
- MiNK Therapeutics, Inc. interest expense for the quarter ending 2026-03-31 was -$4.00K.
- MiNK Therapeutics, Inc. interest expense for the quarter ending 2025-12-31 was -$29.00K.
- MiNK Therapeutics, Inc. interest expense for the quarter ending 2025-09-30 was -$25.00K.
- MiNK Therapeutics, Inc. interest expense for fiscal 2025 was -$110.00K.
- MiNK Therapeutics, Inc. interest expense for fiscal 2024 was -$93.00K.
- MiNK Therapeutics, Inc. interest expense for fiscal 2023 was -$28.00K.
- MiNK Therapeutics, Inc. interest expense for fiscal 2021 was $2.43M, a 0.38% decline from fiscal 2020.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$2.00K 10-Q · filed 2026-08-13 | -$6.00K 10-Q · filed 2026-08-13 | -$35.00K derived: sum of 3 quarters · filed 2026-08-13 | -$60.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$4.00K 10-Q · filed 2026-05-15 | -$33.00K derived: sum of 2 quarters · filed 2026-05-15 | -$58.00K derived: sum of 3 quarters · filed 2026-05-15 | -$85.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$29.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$54.00K derived: sum of 2 quarters · filed 2026-03-31 | -$81.00K derived: sum of 3 quarters · filed 2026-08-13 | -$110.00K 10-K · filed 2026-03-31 |
| 2025-09-30 | -$25.00K 10-Q · filed 2025-11-14 | -$52.00K derived: sum of 2 quarters · filed 2026-08-13 | -$81.00K 10-Q · filed 2025-11-14 | -$111.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$27.00K 10-Q · filed 2026-08-13 | -$55.00K 10-Q · filed 2026-08-13 | -$86.00K derived: sum of 3 quarters · filed 2026-08-13 | -$114.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$29.00K 10-Q · filed 2026-05-15 | -$59.00K derived: sum of 2 quarters · filed 2026-05-15 | -$87.00K derived: sum of 3 quarters · filed 2026-05-15 | -$113.00K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | -$30.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$58.00K derived: sum of 2 quarters · filed 2026-03-31 | -$84.00K derived: sum of 3 quarters · filed 2026-03-31 | -$93.00K 10-K · filed 2026-03-31 |
| 2024-09-30 | -$28.00K 10-Q · filed 2025-11-14 | -$54.00K derived: sum of 2 quarters · filed 2025-11-14 | -$63.00K 10-Q · filed 2025-11-14 | |
| 2024-06-30 | -$26.00K 10-Q · filed 2025-08-14 | -$36.00K 10-Q · filed 2025-08-14 | ||
| 2024-03-31 | -$10.00K 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | -$28.00K 10-K · filed 2025-03-18 | |||
| 2022-03-31 | $848.00 10-Q · filed 2022-05-13 | $2.40K derived: sum of 2 quarters · filed 2022-05-13 | $883.72K derived: sum of 3 quarters · filed 2022-05-13 | |
| 2021-12-31 | $1.55K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | $882.87K derived: sum of 2 quarters · filed 2022-03-18 | $2.43M 10-K · filed 2022-03-18 | |
| 2021-09-30 | $881.32K 10-Q · filed 2021-11-29 | $2.43M 10-Q · filed 2021-11-29 | ||
| 2021-03-31 | $743.70K 10-Q · filed 2022-05-13 | $1.43M derived: sum of 2 quarters · filed 2022-05-13 | $2.07M derived: sum of 3 quarters · filed 2022-05-13 | |
| 2020-12-31 | $686.78K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | $1.33M derived: sum of 2 quarters · filed 2022-03-18 | $2.44M 10-K · filed 2022-03-18 | |
| 2020-09-30 | $639.03K 10-Q · filed 2021-11-29 | $1.75M 10-Q · filed 2021-11-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |